HCPCS code Q5126: Alymsys injection, per 10 mg2026 Medicare rate & RVUs in California

CMS doesn’t publish an office rate for Q5126 in California.

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What Q5126 covers

Alymsys is a bevacizumab biosimilar used intravenously in oncology regimens for selected cancers, including colorectal, non-squamous lung, renal, cervical, and ovarian cancers. Oncology practices, infusion centers, and hospital outpatient departments may report this drug code when Alymsys is administered. The code identifies the specific product, not bevacizumab products generally; use it when Alymsys was the product supplied.

CMS assigns this code physician fee schedule status E, meaning it is excluded from the physician fee schedule. When Medicare covers the drug, it is treated as a Part B drug and generally priced through CMS’s quarterly Average Sales Price drug pricing files; coverage is left to the Medicare contractor’s judgment. Each billing unit represents 10 mg of bevacizumab-maly. Report the administered dose in 10 mg units, and report the infusion administration service separately when furnished and supported by the claim.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where Q5126 pays more and less in California

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

29 of 29 payment localities

How the Q5126 rate is calculated

Each of Q5126’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for Q5126

Q5126 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

Q5126 compared with similar codes

How to choose

Q5118Zirabev injectionPer 10 mg

Q5118 identifies Zirabev (bevacizumab-bvzr); Q5126 identifies Alymsys (bevacizumab-maly). Select the code for the product administered.

Q5129Vegzelma injectionPer 10 mg

Q5129 identifies Vegzelma (bevacizumab-adcd); Q5126 identifies Alymsys. These are distinct bevacizumab biosimilar products.

J9035BevacizumabPer 10 mg

J9035 identifies bevacizumab, while Q5126 is specific to the Alymsys biosimilar. Use the product-specific code matching the drug supplied.

Codes related to Q5126

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates